Table 1.

Demographic and clinical characteristics of autochthonous human alveolar echinococcosis patients in Croatia from 2017 to 2022.

Patient: Gender, Age, Year of Diagnosis	Clinical Presentation (Duration of Symptoms before Diagnosis)	PNM Classification (Clinical Stage)	Diagnosis and Follow Up	Therapy	Complications
No 1: male; 63 y.; 2017	Fever, dyspnea, cough, right-sided chest pain (3 y.)	P4N1M1 (IV)	MSCT Pathohistology Serology PCR FDG-PET	Albendazole; Partial resection; Amphotericin B; Mefloquine	Intraop. bleeding; Pancytopenia, agranulocytosis with sepsis—due to albendazole therapy
No 2: male; 64 y.; 2019	Upper right abdominal quadrant pain; jaundice (5 mo.)	P4N1M0 (IV)	MSCT Pathohistology PCR	Liver lobectomy; Albendazole 2 y. postoperatively	No
No 3: female; 37 y.; 2021	Upper right abdominal quadrant pain (8 mo.)	P4N0M0 (IIIb)	MSCT Pathohistology Serology PCR FDG-PET	Excision; Albendazole postoperatively; Liver transplantation	Postexcisional: hepatic artery thrombosis; recurrent cholangitis
No 4: female; 58 y.; 2022	Upper right abdominal quadrant pain, nausea (2 mo.)	P4N0M0 (IIIb)	MSCT Pathohistology Serology PCR FDG-PET	Albendazole Partial resection	No
No 5: female; 67 y.; 2022	Upper right abdominal quadrant discomfort (8 y.)	P3N0M0 (IIIa)	MSCT Pathohistology Serology PCR FDG-PET	Liver lobectomy; Albendazole postoperatively	Leucopenia; Increased transaminases due to albendazole therapy
No 6: female; 53 y.; 2022	Upper abdominal discomfort, nausea (4 y.)	P2N0M0 (II)	MSCT Serology FDG-PET Pathohistology PCR	Albendazole; Excision	Increased transaminases and neutropenia due to albendazole therapy

y.—years; mo.—months; MSCT—Multi-Slice Computed Tomography; PCR—Polymerase Chain Reaction; FDG-PET—Fluorodeoxyglucose-Positron Emission Tomography.